Login to Your Account

AMT Shares Plunge on Second Rejection of Glybera

By Cormac Sheridan

Monday, October 24, 2011
Amsterdam Molecular Therapeutics (AMT) N.V'.s bid to become the first Western biotechnology firm to gain a gene therapy approval suffered a second rebuff, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) stood over its original negative opinion on a marketing authorization application for Glybera (alipogene tiparvovec), which is in development for the ultra-rare indication lipoprotein lipase deficiency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription